Biomaterial Database

Reduction of p24 antigen levels in asymptomatic patients using twice-daily zidovudine. 1989

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

UI	MeSH Term	Description	Entries
D008297	Male		Males
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163	Acquired Immunodeficiency Syndrome	An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D012191	Retroviridae Proteins	Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein.	Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus
D015215	Zidovudine	A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.	AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015488	HIV Antigens	Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.	AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D016655	HIV Core Protein p24	A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.	HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.

February 1991, Genitourinary medicine,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.

August 1990, The Netherlands journal of medicine,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Combination treatment of wellferon and zidovudine in asymptomatic HIV p24 Ag positive patients.

December 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children.

December 2004, The Journal of antimicrobial chemotherapy,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.

September 1990, AIDS (London, England),

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine.

December 1992, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.

October 2007, Antimicrobial agents and chemotherapy,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.

April 1995, AIDS research and human retroviruses,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

April 2009, AIDS research and therapy,

S Gill, and N Thin, and M Cordery, and B Spacey, and D Barlow

[Zidovudine for asymptomatic HIV patients?].

October 1994, Deutsche medizinische Wochenschrift (1946),